1374641-74-3

Basic information

• Product Name: Benzenamine, 3-[(2,5-dichloro-4-pyrimidinyl)oxy]-
• Synonyms: Benzenamine, 3-[(2,5-dichloro-4-pyrimidinyl)oxy]-
• CAS NO: 1374641-74-3
• Molecular Weight: 256.091
• EINECS: -0
• Mol File: 1374641-74-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzenamine, 3-[(2,5-dichloro-4-pyrimidinyl)oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 3-[(2,5-dichloro-4-pyrimidinyl)oxy]-(1374641-74-3)
• EPA Substance Registry System: Benzenamine, 3-[(2,5-dichloro-4-pyrimidinyl)oxy]-(1374641-74-3)

Safety Data

• Hazardous Substances Data: 1374641-74-3(Hazardous Substances Data)

Upstream product

• 76661-24-0 2,5-dichloro-4-(3-nitrophenoxy)pyrimidine 
• 554-84-7 meta-nitrophenol 
• 5750-76-5 2,4,5-trichloropyrimidine 
• 591-27-5 m-Hydroxyaniline 

Downstream Products

• 1436851-28-3 C₂₈H₃₁ClN₆O₅ 
• 1436851-29-4 2-(4-(4-((4-(3-acrylamidophenoxy)-5-chloropyrimidin-2-yl)-amino)-3-methoxyphenyl)piperazin-1-yl)acetic acid 
• 1436851-31-8 C₃₆H₃₆ClN₉O₉S 
• 1436851-32-9 C₃₇H₃₈ClN₉O₉S 
• 1436851-33-0 C₄₀H₄₃ClN₁₀O₉S 
• 1436851-34-1 C₃₉H₄₀ClN₉O₉S 
• 1436851-35-2 C₃₇H₃₈ClN₉O₉S 
• 1436851-36-3 C₃₆H₃₅ClN₈O₁₀S 
• 1436851-37-4 C₃₇H₃₇ClN₈O₁₀S 
• 1436851-38-5 C₃₈H₃₉ClN₈O₁₀S 
• 1374641-75-4 N-(3-((2,5-dichloropyrimidin-4-yl)oxy)phenyl)acrylamide 
• 1436851-41-0 C₄₀H₄₃ClN₈O₁₀S 
• 1436851-40-9 C₃₈H₃₉ClN₈O₁₁S 
• 1436851-39-6 C₃₈H₃₅ClN₈O₁₀S 

Relevant articles and documents

Deuterated pyrimidine derivative with anti-cancer effect

The invention relates to a deuterated pyrimidine derivative with an anti-cancer effect, and belongs to the field of medicines. The invention aims to solve the problems that the in-vivo half-life period of an anti-cancer drug WZ4002 is too short, the blood

Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer

A series of hybrids (12a-k) from (phenylsulfonyl)furoxan and anilinopyrimidine were synthesized and biologically evaluated as epidermal growth factor receptor (EGFR) inhibitors for intervention of non-small-cell lung cancer (NSCLC). Compound 12k exhibited